Successful olaparib desensitization using a novel one-day protocol

BACKGROUND: Olaparib is a revolutionary treatment for patients with ovarian and breast cancer. Currently, there is no established 1-day drug desensitization protocol for patients with olaparib type-1 hypersensitivity reactions despite well documented IgE-mediated adverse reactions occurring with ola...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Rongbo, Welch, Stephen, Roberts, Hannah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659133/
https://www.ncbi.nlm.nih.gov/pubmed/33292483
http://dx.doi.org/10.1186/s13223-020-00499-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659133/
https://www.ncbi.nlm.nih.gov/pubmed/33292483
http://dx.doi.org/10.1186/s13223-020-00499-x

Ejemplares similares